For the best experience on the Abcam website please upgrade to a modern browser such as Google Chrome
If you continue without changing your cookie settings, we'll assume you’re happy with this.
Pancreatic cancer is the seventh leading cause of cancer-related death worldwide with a higher death toll in developed countries. The most common subtype of pancreatic cancer is pancreatic ductal adenocarcinoma, accounting for approximately 85% of all cases. Globally the mortality rate coincides with the incidence rate, emphasizing the poor prognosis for this cancer type (Hasan et al, 2019). Immunohistochemistry offers a useful assay in the identification and classification of pancreatic neoplasms. The diagnostic accuracy for this cancer type has been significantly improved by the continuous discovery and validation of new tumor-associated biomarkers and the development of effective immunohistochemical panels. Application of appropriate IHC panels allows pathologists to differentiate between the different types of pancreatic cancer and to distinguish pancreatic carcinomas from other secondary metastatic cancers (Lin et al, 2015).
S100P is a sensitive and specific diagnostic biomarker for pancreatic cancer. It has a potential role in the proliferation, survival, motility and invasiveness of pancreatic cells. Levels of S100P expression increase during the progression from pancreatic intraepithelial neoplasia to invasive adenocarcinoma. This biomarker can be used to differentiate between positive pancreatic adenocarcinoma and negative pancreatic endocrine tumors.
Formalin-fixed paraffin-embedded human pancreatic adenocarcinoma tissue labeled with Anti-S100P (ab133554) at 1:250 in IHC.
Recommended IHC antibody:Recombinant Anti-S100P antibody [EPR6143] (ab133554)
Also known as Epithelial Membrane Antigen (EMA), CD227 and episialin. In normal cells, MUC1 acts as barrier to the apical surface of epithelial cells, playing a protective and regulatory role. In pancreatic adenocarcinoma, MUC1 is highly expressed and associated with poor patient prognosis (Nath et al, 2013).
Recommended IHC antibody:Recombinant Anti-MUC1 antibody [EPR1023] (ab109185)
Mesothelin (MSLN) is expressed on the surface of pancreatic adenocarcinoma cells and may play a role in cell adhesion. It serves as a diagnostic and prognostic biomarker for pancreatic cancer and may be used to target immunotherapy. Mesothelin expression in pancreatic adenocarcinoma is associated with high tumor aggressiveness and poor patient outcome (Inaguma et al, 2017).